Prevention of relapse in residual depression by cognitive therapy: a controlled trial
- PMID: 12884889
- DOI: 10.1001/archpsyc.56.9.829
Prevention of relapse in residual depression by cognitive therapy: a controlled trial
Abstract
Background: Previous studies indicate that depressed patients with partial remission and residual symptoms following antidepressant treatment are common and have high rates of relapse. There is evidence that cognitive therapy may reduce relapse rates in depression.
Methods: One hundred fifty-eight patients with recent major depression, partially remitted with antidepressant treatment (mean daily doses equivalent to 185 mg of amitriptyline or 33 mg of fluoxetine) but with residual symptoms of 2 to 18 months' duration, were included in a controlled trial. Subjects were randomized to receive clinical management alone or clinical management plus cognitive therapy for 16 sessions during 20 weeks, with 2 subsequent booster sessions. Subjects were assessed regularly throughout the 20 weeks' treatment and for a further year. They received continuation and maintenance antidepressants at the same dose throughout.
Results: Cognitive therapy reduced relapse rates for acute major depression and persistent severe residual symptoms, in both intention to treat and treated per protocol samples. The cumulative relapse rate at 68 weeks was reduced significantly, from 47% in the clinical management control group to 29% with cognitive therapy (hazard ratio 0.54; 95% confidence interval, 0.32-0.93; intention to treat analysis). Cognitive therapy also increased full remission rates at 20 weeks but did not significantly improve symptom ratings.
Conclusion: In this difficult-to-treat group of patients with residual depression who showed only partial response despite antidepressant treatment, cognitive therapy produced worthwhile benefit.
Similar articles
-
Effects of adding cognitive therapy to fluoxetine dose increase on risk of relapse and residual depressive symptoms in continuation treatment of major depressive disorder.J Clin Psychopharmacol. 2002 Oct;22(5):474-80. doi: 10.1097/00004714-200210000-00006. J Clin Psychopharmacol. 2002. PMID: 12352270 Clinical Trial.
-
Prevention of recurrent depression with cognitive behavioral therapy: preliminary findings.Arch Gen Psychiatry. 1998 Sep;55(9):816-20. doi: 10.1001/archpsyc.55.9.816. Arch Gen Psychiatry. 1998. PMID: 9736008 Clinical Trial.
-
Effectiveness of preventive cognitive therapy while tapering antidepressants versus maintenance antidepressant treatment versus their combination in prevention of depressive relapse or recurrence (DRD study): a three-group, multicentre, randomised controlled trial.Lancet Psychiatry. 2018 May;5(5):401-410. doi: 10.1016/S2215-0366(18)30100-7. Epub 2018 Apr 3. Lancet Psychiatry. 2018. PMID: 29625762 Clinical Trial.
-
Novel Augmentation Strategies in Major Depression.Dan Med J. 2017 Apr;64(4):B5338. Dan Med J. 2017. PMID: 28385173 Review.
-
Efficacy in long-term treatment of depression.J Clin Psychiatry. 1996;57 Suppl 2:24-30. J Clin Psychiatry. 1996. PMID: 8626360 Review.
Cited by
-
Prevalence and outcome of partial remission in depression.J Psychiatry Neurosci. 2002 Jul;27(4):241-7. J Psychiatry Neurosci. 2002. PMID: 12174733 Free PMC article. Review.
-
Long-term outcomes of trials in the National Institute for Health and Care Excellence depression guideline.BJPsych Open. 2019 Sep 9;5(5):e81. doi: 10.1192/bjo.2019.65. BJPsych Open. 2019. PMID: 31685073 Free PMC article.
-
Treatment of recurrent depression: a sequential psychotherapeutic and psychopharmacological approach.CNS Drugs. 2003;17(15):1109-17. doi: 10.2165/00023210-200317150-00005. CNS Drugs. 2003. PMID: 14661988 Review.
-
Global Research Trends and Hotspots Analysis of the Scientific Production of Amitriptyline: A Bibliometric Approach.Pharmaceuticals (Basel). 2023 Jul 24;16(7):1047. doi: 10.3390/ph16071047. Pharmaceuticals (Basel). 2023. PMID: 37513958 Free PMC article.
-
Therapeutic options for treatment-resistant depression.CNS Drugs. 2010 Feb;24(2):131-61. doi: 10.2165/11530280-000000000-00000. CNS Drugs. 2010. PMID: 20088620 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical